Founded
Address
TVM Capital Corp
101 Arch Street
Suite 1950
Boston, MA 02110
United States
Phone
Website
Recent investment activity
KANDO id: 2093
Funding rounds
Actual initial investment stage
N/A (1)
Investment activity status
Active investor
Selected investments
Displaying 26 - 47 of 47| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Sequenom Inc | Biotechnology tools and diagnostics company. | N/A | |||
|
|
Transave Inc | N/A | ||||
|
|
TransMolecular Inc | TransMolecular is a biotechnology company. | N/A | |||
|
|
Ubidyne Inc | Developer of an antenna embedded digital radio tech. | Series B | |||
|
|
Ubidyne Inc | Developer of an antenna embedded digital radio tech. | Series A | |||
|
|
VPIsystems Inc | Venture | ||||
|
|
VPIsystems Inc | Series C | ||||
|
|
Acorda Therapeutics Inc | A biotechnology company whose mission is to develop and market therapeutic products for spinal cord injury and other central nervous system disorders. | N/A | |||
|
|
Altor Bioscience Corp | Biopharmaceutical company developing a new class of therapeutic products for the treatment of cancer, viral infections and autoimmune diseases. | N/A | |||
|
|
Bitwave Semiconductor Inc | Series B Follow-on investment | ||||
|
|
Bitwave Semiconductor Inc | Series A | ||||
|
|
Cambridge Broadband Networks Ltd | Venture | ||||
|
|
Cambridge Broadband Networks Ltd | Series D | ||||
|
|
Cerenis Therapeutics SA | Series C | ||||
|
|
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series C | |||
|
|
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series B | |||
|
|
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series A | |||
|
|
Coreoptics Inc | Venture | ||||
|
Enigma Semiconductor Inc | Developer of next-generation switching solutions. | N/A Initial investment | |||
|
|
Sirtris Pharmaceuticals Inc | Series C | ||||
|
|
Sirtris Pharmaceuticals Inc | Series B | ||||
|
|
Sirtris Pharmaceuticals Inc | Series A |